Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts. Show more
Location: 500 River Ridge Drive, Norwood, MA, 02062, United States | Website: https://www.corbuspharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
87.62M
52 Wk Range
$4.64 - $61.90
Previous Close
$7.16
Open
$7.16
Volume
270,775
Day Range
$7.16 - $7.76
Enterprise Value
-45.5M
Cash
132.8M
Avg Qtr Burn
-12.56M
Insider Ownership
0.71%
Institutional Own.
93.23%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CRB-913 Details Obesity | Phase 1 Data readout | |
CRB-701 (SYS6002) Details Solid tumor/s, Urothelial cancer, Cancer | Phase 1 Data readout | |
CRB-601 (anti-αvβ8) Details Solid tumor/s | Phase 1 Update | |
Lenabasum (JBT-101) Details Autoimmune disease | Failed Discontinued | |
Lenabasum Details Genetic disorder, Chronic inflammatory disorder, Rare genetic disease, Inflammatory disease | Failed Discontinued | |
Lenabasum Details Cystic fibrosis | Failed Discontinued | |
Lenabasum Details Systemic sclerosis | Failed Discontinued |